Fosnetupitant is primarily used in the prevention of chemotherapy-induced nausea and vomiting (CINV). It is often administered in combination with other antiemetic agents to enhance its efficacy. The drug works by inhibiting the neurokinin-1 (NK1) receptor, which plays a key role in the vomiting reflex triggered by chemotherapy. This makes it particularly useful for patients undergoing highly emetogenic chemotherapy regimens, such as those involving cisplatin. Fosnetupitant is typically given as an intravenous infusion, ensuring rapid and consistent absorption, which is crucial for managing acute and delayed phases of CINV. Its application is especially valuable in improving the quality of life for cancer patients by reducing the debilitating side effects of chemotherapy.